Assessment of Early Response to Tumor-treating Fields in Newly Diagnosed Glioblastoma Using Physiologic and Metabolic MRI: Initial Experience

Overview

Journal CNS Oncol

Specialty Oncology

Date 2016 Apr 15

PMID 27076281

Citations 13

Authors

Suyash Mohan

Sanjeev Chawla

Sumei Wang

Gaurav Verma

Aaron Skolnik

Steven Brem

Katherine B Peters

Harish Poptani

Affiliations

Soon will be listed here.

Abstract

Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis. Additionally, a reduction in choline/creatine was also noted during this period. These preliminary data indicate the potential of physiologic and metabolic MRI in assessing early treatment response to TTFields in combination with temozolamide.

Citing Articles

Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.

Iv M, Naya L, Sanan S, Van Buskirk S, Nagpal S, Thomas R Neuroradiol J. 2023; 37(1):107-118.

PMID: 37931176 PMC: 10863570. DOI: 10.1177/19714009231207083.

Therapeutic potential of tumor treating fields for malignant brain tumors.

Zhou Y, Xing X, Zhou J, Jiang H, Cen P, Jin C Cancer Rep (Hoboken). 2023; 6(5):e1813.

PMID: 36987739 PMC: 10172187. DOI: 10.1002/cnr2.1813.

Challenges and opportunities for advanced neuroimaging of glioblastoma.

Henssen D, Meijer F, Verburg F, Smits M Br J Radiol. 2022; 96(1141):20211232.

PMID: 36062962 PMC: 10997013. DOI: 10.1259/bjr.20211232.

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.

Guo X, Yang X, Wu J, Yang H, Li Y, Li J Cancers (Basel). 2022; 14(15).

PMID: 35954334 PMC: 9367615. DOI: 10.3390/cancers14153669.

Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism.

Kumar M, Nanga R, Verma G, Wilson N, Brisset J, Nath K Front Neurol. 2022; 13:789355.

PMID: 35370872 PMC: 8967433. DOI: 10.3389/fneur.2022.789355.

References

Lee S, Kim J, Kim Y, Lee G, Lee E, Park I . Perfusion MR imaging in gliomas: comparison with histologic tumor grade. Korean J Radiol. 2001; 2(1):1-7. PMC: 2718089. DOI: 10.3348/kjr.2001.2.1.1. View

Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V . NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012; 48(14):2192-202. DOI: 10.1016/j.ejca.2012.04.011. View

Schmainda K, Prah M, Connelly J, Rand S, Hoffman R, Mueller W . Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014; 16(6):880-8. PMC: 4022214. DOI: 10.1093/neuonc/not216. View

Kitahara S, Nakasu S, Murata K, Sho K, Ito R . Evaluation of treatment-induced cerebral white matter injury by using diffusion-tensor MR imaging: initial experience. AJNR Am J Neuroradiol. 2005; 26(9):2200-6. PMC: 7976122. View

Pless M, Weinberg U . Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs. 2011; 20(8):1099-106. DOI: 10.1517/13543784.2011.583236. View

Beppu T, Inoue T, Shibata Y, Yamada N, Kurose A, Ogasawara K . Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol. 2005; 63(1):56-61. DOI: 10.1016/j.surneu.2004.02.034. View

Jackson E, Barboriak D, Bidaut L, Meyer C . Magnetic resonance assessment of response to therapy: tumor change measurement, truth data and error sources. Transl Oncol. 2009; 2(4):211-5. PMC: 2781079. DOI: 10.1593/tlo.09241. View

Young R, Jamshidi A, Davis G, Sherman J . Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 2015; 3(9):121. PMC: 4481356. DOI: 10.3978/j.issn.2305-5839.2015.05.10. View

Kirson E, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y . Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004; 64(9):3288-95. DOI: 10.1158/0008-5472.can-04-0083. View

10.

Aquino D, Di Stefano A, Scotti A, Cuppini L, Anghileri E, Finocchiaro G . Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One. 2014; 9(3):e90535. PMC: 3968002. DOI: 10.1371/journal.pone.0090535. View

11.

Saraswathy S, Crawford F, Lamborn K, Pirzkall A, Chang S, Cha S . Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2008; 91(1):69-81. PMC: 3022437. DOI: 10.1007/s11060-008-9685-3. View

12.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

13.

Miller B, Chang L, Booth R, Ernst T, Cornford M, Nikas D . In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996; 58(22):1929-35. DOI: 10.1016/0024-3205(96)00182-8. View

14.

Chawla S, Wang S, Kim S, Sheriff S, Lee P, Rengan R . Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience. J Neuroimaging. 2013; 25(1):97-104. DOI: 10.1111/jon.12070. View

15.

Stupp R, Taillibert S, Kanner A, Kesari S, Steinberg D, Toms S . Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015; 314(23):2535-43. DOI: 10.1001/jama.2015.16669. View

16.

Chen H, Liu R, Liu J, Tang J . Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms. J Int Med Res. 2012; 40(1):85-94. DOI: 10.1177/147323001204000109. View

17.

Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S . Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage. 2008; 43(1):29-35. DOI: 10.1016/j.neuroimage.2008.06.041. View

18.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

19.

Muruganandham M, Clerkin P, Smith B, Anderson C, Morris A, Capizzano A . 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 90(1):181-9. PMC: 4183193. DOI: 10.1016/j.ijrobp.2014.05.014. View

20.

Liu X, Duan C, Fu W, Niu L, Li Y, Sui Q . Correlation between magnetic resonance perfusion weighted imaging of radiation brain injury and pathology. Genet Mol Res. 2015; 14(4):16317-24. DOI: 10.4238/2015.December.8.23. View